Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

被引:20
|
作者
Wulffelé, MG
Kooy, A
Lehert, P
Bets, D
Donker, AJM
Stehouwer, CDA
机构
[1] Bethesda Gen Hosp, Dept Internal Med, NL-7909 AA Hoogeveen, Netherlands
[2] FUCAM, Dept Stat, Fac Econ, Mons, Belgium
[3] E Merck Nederland BV, Clin Res & Dev, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands
[6] Univ Hosp Maastricht, Dept Med, Maastricht, Netherlands
关键词
blood pressure; metformin; randomized controlled trial; Type; 2; diabetes; 24-h ambulatory blood pressure monitoring;
D O I
10.1111/j.1464-5491.2005.01554.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We investigated in a double-blind study whether metformin reduces blood pressure (BP) in patients with Type 2 diabetes intensively treated with insulin. Methhods A total of 220 patients with Type 2 diabetes were asked to undergo 24-h ambulatory BP monitoring (24-h ABPM). One hundred and eighty-two gave informed consent. Eighty-nine were randomized to metformin and 93 to placebo. Thirty-five subjects dropped out (13 placebo, 22 metformin users); 147 patients underwent a second 24-h ABPM, 16 weeks after randomization. Results Systolic BP (SBP), diastolic BP (DBP), pulse BP (PP), mean BP (MP) and heart rate (HR) were measured as office BP measurements and as 24-h ABPM for 24-h, day and night. Office BP measurements did not differ significantly between the placebo- and metformin-treated groups for any BP measure, but showed a non-significant trend for SBP reduction with metformin use (mean baseline-adjusted difference, metformin minus placebo: -4.2 mmHg, 95% CI, -9.9 to +1.5; P = 0.15). The baseline-adjusted differences of the ambulatory measurements were -0.2 mmHg (95% CI, -2.9 to +2.6) for the 24-h SBP, and +1.1 mmHg (95% CI, -0.7 to +2.8) for the 24-h DBP. On the whole, BP differences between metformin- and placebo-treated groups were not statistically significant. The only significant difference was for night-time PP (baseline-adjusted difference: -2.2 mmHg; 95% CI, -4.2 to -0.2). These results were not different after adjustment for age and diabetes duration, or for (changes in) body mass index, glycated haemoglobin, insulin dose or plasma homocysteine. Conclusion Metformin does not significantly affect BP in patients with Type 2 diabetes intensively treated with insulin.
引用
收藏
页码:907 / 913
页数:7
相关论文
共 50 条
  • [31] Insulin glargine or NPH combined with metformin in type 2 diabetes:: the LANMET study
    Yki-Järvinen, H
    Kauppinen-Mäkelin, R
    Tiikkainen, M
    Vähätalo, M
    Virtamo, H
    Nikkilä, K
    Tulokas, T
    Hulme, S
    Hardy, K
    McNulty, S
    Hänninen, J
    Levänen, H
    Lahdenperä, S
    Lehtonen, R
    Ryysy, L
    DIABETOLOGIA, 2006, 49 (03) : 442 - 451
  • [32] Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
    Barnett, Anthony H.
    Charbonnel, Bernard
    Donovan, Mark
    Fleming, Douglas
    Chen, Roland
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) : 513 - 523
  • [33] Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin
    Stefanovic, V
    Antic, S
    Mitic-Zlatkovic, M
    Vlahovic, P
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 1999, 15 (06) : 400 - 404
  • [34] Impaired nocturnal blood pressure dipping in patients with type 2 diabetes mellitus
    Kim, Yu-Sok
    Davis, Shyrin C. A. T.
    Stok, Wim J.
    van Ittersum, Frans J.
    van Lieshout, Johannes J.
    HYPERTENSION RESEARCH, 2019, 42 (01) : 59 - 66
  • [35] Inflammatory cytokines in insulin-treated patients with type 2 diabetes
    Mavridis, G.
    Souliou, E.
    Diza, E.
    Symeonidis, G.
    Pastore, F.
    Vassiliou, A. M.
    Karamitsos, D.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2008, 18 (07) : 471 - 476
  • [36] Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin
    Dailey, G. E.
    Gao, L.
    Aurand, L.
    Garg, S. K.
    DIABETES OBESITY & METABOLISM, 2013, 15 (12) : 1085 - 1092
  • [37] Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes
    Yen, Fu-Shun
    Hsu, Chih-Cheng
    Hu, Kai-Chieh
    Hung, Yu-Tung
    Hsu, Chung Y.
    Wei, James Cheng-Chung
    Hwu, Chii-Min
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (17)
  • [38] Effect of Metformin on Methylglyoxal Metabolism in Patients with Type 2 Diabetes
    Kender, Z.
    Fleming, T.
    Kopf, S.
    Torzsa, P.
    Grolmusz, V.
    Herzig, S.
    Schleicher, E.
    Racz, K.
    Reismann, P.
    Nawroth, P. P.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (05) : 316 - 319
  • [39] The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes
    Khan, A. S. A.
    McLoughney, C. R.
    Ahmed, A. B.
    DIABETIC MEDICINE, 2006, 23 (10) : 1079 - 1084
  • [40] Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
    Ahmad, Ehtasham
    Sargeant, Jack A.
    Zaccardi, Francesco
    Khunti, Kamlesh
    Webb, David R.
    Davies, Melanie J.
    PHARMACEUTICALS, 2020, 13 (12) : 1 - 26